How a new drug may improve thinking and motivation in primates
Muscarinic modulation of RDoC constructs in primate behavior and fronto-striatal circuits
This study is looking at how a new drug might help improve thinking skills, motivation, and self-control in monkeys, which could lead to better treatments for people with conditions like schizophrenia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11037884 on NIH RePORTER |
What this research studies
This research investigates how a specific drug can enhance cognitive abilities, motivation, and behavioral regulation in nonhuman primates. The study focuses on a positive allosteric modulator for the muscarinic M1 receptor, which may help reduce side effects associated with current treatments for conditions like schizophrenia. By examining the drug's effects on brain chemistry and behavior, researchers aim to understand its potential benefits for cognitive and motivational deficits. The findings could lead to improved treatment options for patients with similar challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who experience cognitive deficits and lack of motivation.
Not a fit: Patients who do not have schizophrenia or related cognitive and motivational issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cognitive function and motivation in patients with schizophrenia and related disorders.
How similar studies have performed: Previous research has shown promise in using muscarinic modulation to enhance cognitive functions, suggesting potential for success in this approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Womelsdorf, Thilo — Vanderbilt University
- Study coordinator: Womelsdorf, Thilo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.